Membrane-targeted therapeutics for Alzheimer's disease: lipid-based neuroprotection platform

Overview

This research platform addresses Alzheimer's disease (AD) through an innovative membrane-centric approach, targeting the neuronal cell membrane as a critical site of amyloid beta (Aβ) toxicity. The work is based on a novel hypothesis that Aβ may function similarly to antimicrobial peptides (AMPs), recognizing and attacking neuronal membranes when their lipid composition changes due to aging or disease. By understanding how membrane composition shifts trigger amyloid recognition and damage, the research team aims to develop protective interventions using membrane-active molecules and lipid-altering strategies to prevent AD progression.

The platform offers significant potential for pharmaceutical and biotechnology partners seeking novel therapeutic targets in neurodegeneration. Early findings demonstrate that membrane models mimicking AD states are more susceptible to amyloid damage than healthy models, and that protective molecules such as melatonin and trehalose can effectively shield vulnerable membranes.

Technical specifications

Key research capabilities and findings:

• Model membrane systems replicating healthy neuronal membranes (POPC/SM/GM1/Chol composition) and AD-affected membranes (POPC/SM/Chol composition)
• Bacterial membrane models mimicking pathogens such as Streptococcus pneumoniae (DOPG/TOCL/POPE composition) for comparative studies
• Advanced analytical techniques including atomic force microscopy (AFM), surface plasmon resonance (SPR), and black lipid membrane (BLM) electrophysiology for studying membrane-amyloid interactions
• Nanoscale domain analysis revealing how lipid composition changes influence membrane organization and vulnerability to amyloid attack
• Oxidative stress modeling using reactive oxygen species (H2O2) to simulate inflammatory conditions affecting membranes
• Comparative peptide studies examining the mechanism of action of LL-37 (antimicrobial peptide) versus Aβ 1-42 across membrane models
• Protective molecule screening for membrane-active compounds including melatonin and trehalose that demonstrate efficacy against early-stage AD membrane damage

Technology readiness level

This research is currently at Technology Readiness Level 3-4, with proof-of-concept established through validated membrane models and demonstrated protective effects of candidate molecules in laboratory settings. The team has confirmed that healthy membrane models resist amyloid damage more effectively than AD-mimicking models, and that small membrane-active molecules can protect membranes representing early AD stages. The proposed two-year validation program will extend findings to bacterial membrane comparisons and test additional protective compounds. The platform is positioned for collaborative partnerships with organizations providing lipidomics analysis capabilities and synthetic molecule libraries for therapeutic development.